Dapoxetine for premature ejaculation: Advances in clinical studies / 中华男科学杂志
National Journal of Andrology
;
(12): 931-936, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-275992
ABSTRACT
Premature ejaculation (PE) is a most common sexual dysfunction, for which dapoxetine, a novel selective serotonin (5-HT) re-uptake inhibitor (SSRI), is the only licensed oral medicine at present. With the advantages of fast absorption, rapid action, on-demand medication, and short half-life time, dapoxetine has been proved by clinical trials to be effective in prolonging the intravaginal ejaculation latency time (IELT) and improving the overall condition of PE patients in various areas and populations. Compared with the traditional SSRIs, dapoxetine has a better safety and tolerability. The most frequently reported dapoxetine-related adverse events include nausea, diarrhea, headache and dizziness, but with very few severe or serious cases.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Tempo de Reação
/
Benzilaminas
/
Resultado do Tratamento
/
Inibidores Seletivos de Recaptação de Serotonina
/
Pesquisa Biomédica
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Ejaculação
/
Ejaculação Precoce
/
Naftalenos
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS